Smart Inhalers Market size was
valued to be at $34 million in 2018 and is expected to increase during the
forecast period to be at $1,406 million by 2026, registering a CAGR of 58.4%
from 2019 to 2026. The inhalers segment accounted for more than half of the
total market share in 2018.
Smart
inhalers are the small inhaler devices used for delivering several inhaled
medications such as anticholinergics, glucocorticoids, and beta antagonists.
According to CDC data of 2016, approximately 26.5 million people are living
with asthma in the U.S., and nearly 1.7 million people were found out to be
having asthma as the primary diagnosis during their visit to emergency
departments. Smart inhalers contain sensors that are connected to inhaler
devices, this allows maintaining the record of inhaler, increasing the
adherence and monitoring of the patient.
Download PDF Report
Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/4600
The major factor attributing to the increase
of smart inhalers is rise in prevalence of COPD and asthma, among which COPD is
expected to be the third leading cause of death globally by 2030. Better
treatment option, ease of use, and technological advancements coupled with
increase in adherence rate of patients to smart inhalers are other major
factors that drive this market. However, lack of reimbursement for smart
inhalers and limited availability of smart inhalers in developing regions are
expected to restrain the global smart inhalers market growth.
Currently,
Adherium is the major player in this market with majority of the approved
products being provided by Adherium. However, smart inhalers being a lucrative
market, acquisitions and collaborations are increasing between the
pharmaceutical companies and smart inhaler manufacturers.
Based on
distribution channel, the market is segmented into hospitals, retail
pharmacies, and online pharmacies. Retail pharmacies segment is the highest
contributor for the distribution channel segment. However, online pharmacies
segment is the highest growing segment and is expected to propagate at a higher
growth rate throughout the forecast period, owing to the preference over other
pharmacies, as it provides hassle free doorstep delivery of the smart inhalers
directly by the manufacturing companies.
Key Findings of the Smart Inhalers
Market Study:
- North America
occupied more than one-third share of the global smart inhalers market in
2018.
- The inhalers
segment is the highest contributor in the product segment.
- The online
pharmacies in the distribution channel segment is anticipated to grow with
the highest CAGR throughout the forecast period.
- The hospitals in
the distribution channel segment accounted for three-fourths share of the
market in 2018.
- The nebulizers in
the by product segment is anticipated to grow with the highest rate
throughout the forecast period.
- Asthma in by
indication type segment accounted for the largest growth for the market.
This
report provides a comprehensive analysis of the key players operating in this
market. These include Adherium, Astrazeneca plc., Glaxo Smith Kline, Cohero
Health Inc., Novartis International AG, ResMed Inc., Opko Health Inc.,
Boehringer Ingelheim Group, and Vectura Group plc.

No comments:
Post a Comment